| | | Single nucleotide variant (missense variant) | Melanoma, cutaneous malignant, susceptibility to, 5 +4 more | |
| | | Single nucleotide variant (missense variant) | Melanoma, cutaneous malignant, susceptibility to, 5 +3 more | |
| | | Single nucleotide variant (missense variant) | Melanoma, cutaneous malignant, susceptibility to, 5 +5 more | |
| | | Single nucleotide variant (missense variant) | Increased analgesia from kappa-opioid receptor agonist, female-specific +4 more | |
| | | Single nucleotide variant (missense variant) | not provided +4 more | |
| | | Single nucleotide variant (missense variant) | Tyrosinase-positive oculocutaneous albinism +3 more | |
| | | Single nucleotide variant (missense variant) | Melanoma, cutaneous malignant, susceptibility to, 5 +3 more | GConflicting classifications of pathogenicity |
| | | Single nucleotide variant (missense variant) | Skin/hair/eye pigmentation, variation in, 2 +5 more | |
| | | Single nucleotide variant (missense variant) | not specified +5 more | |
| | | Single nucleotide variant (missense variant) | Tyrosinase-positive oculocutaneous albinism +3 more | |
| | | Single nucleotide variant (missense variant) | Melanoma, cutaneous malignant, susceptibility to, 5 +3 more | |
| | | Single nucleotide variant (missense variant) | Increased analgesia from kappa-opioid receptor agonist, female-specific +4 more | |
| | | Single nucleotide variant (missense variant) | Melanoma, cutaneous malignant, susceptibility to, 5 +3 more | |
| | | Single nucleotide variant (synonymous variant) | not specified +4 more | |
| | | Single nucleotide variant (missense variant) | Tyrosinase-positive oculocutaneous albinism +3 more | |